AQR Arbitrage’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

AQR Arbitrage’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-45,832	Closed	-$1.86K	–	1071
2023 Q1	$1.86K	Hold	45,832	–	–	﹤0.01%	1023
2022 Q4	$2.34K	Hold	45,832	–	–	﹤0.01%	1109
2022 Q3	$2K	Hold	45,832	–	–	﹤0.01%	1367
2022 Q2	$3K	Hold	45,832	–	–	﹤0.01%	1432
2022 Q1	$8K	Hold	45,832	–	–	﹤0.01%	1289
2021 Q4	$447K	Hold	45,832	–	–	0.01%	944
2021 Q3	$33K	Buy	+45,832	New	+$39.3K	﹤0.01%	997

AQR Arbitrage's EUCRW Position: Q2 2023 in Review

AQR Arbitrage sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 45,832 shares — an estimated $1.86K sold.

AQR Arbitrage first reported a position in EUCRW in Q3 2021 and held it in 7 quarters. The position peaked at $447K in Q4 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

AQR Arbitrage reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
AQR Arbitrage sold 45,832 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1.86K.
AQR Arbitrage first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q3 2021 and held it in 7 quarters.
AQR Arbitrage's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $447K in Q4 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on AQR Arbitrage's 13F filing for Q2 2023, filed 14 Aug 2023.